ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
September 04, 2019 21:10 ET
|
Schall Law
LOS ANGELES, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics,...
MacroGenics to Participate in Upcoming Investor Conferences
August 29, 2019 16:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Aug. 29, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
August 28, 2019 14:05 ET
|
Schall Law
LOS ANGELES, Aug. 28, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics,...
MacroGenics to Participate in Upcoming Investor Conferences
August 08, 2019 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
July 31, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Second Quarter 2019 Financial Results Conference Call
July 24, 2019 16:01 ET
|
MacroGenics, Inc.
Rockville, Md., July 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
July 17, 2019 16:01 ET
|
MacroGenics, Inc.
Enrollment of Phase 1 monotherapy expansion cohort completed; presentation of data expected 2H2019End of Phase 1 meeting requested with FDA to discuss program and future development plansInitiation of...
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
July 10, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
MacroGenics to Participate in Jefferies Healthcare Conference
May 30, 2019 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
May 28, 2019 16:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...